MBX — MBX Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1776111 ·
Last close
$66.39
Market Cap
$3.20B
52W High
$72.64
52W Low
$28.00
ADV30
579,674
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -40,931,000 | -37,095,000 | 435,909,000 | 54,124,000 | 26,370,000 |
| Mar 2026 | 0 | — | -27,265,000 | -23,517,000 | 452,701,000 | 45,214,000 | 14,945,000 |
| Dec 2025 | 0 | — | -25,795,000 | -22,062,000 | 385,144,000 | 75,289,000 | 15,921,000 |
| Sep 2025 | 0 | — | -23,926,000 | -21,618,000 | 400,076,000 | 223,125,000 | 12,538,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-82,667,000
Investing CF
$-180,804,000
Financing CF
$278,018,000
CapEx
$-2,530,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.40
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-285,088,000
Inventory
—
Receivables
$3,043,000
ST Investments
$364,457,000
EBIT TTM
$-117,917,000
Pretax Income TTM
$-104,292,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -98,055,000 | -86,971,000 | 385,144,000 | 15,921,000 | — | -79,949,000 |
| Dec 2024 | 0 | -68,194,000 | -61,922,000 | 268,535,000 | 11,093,000 | — | -54,681,000 |
| Dec 2023 | 0 | -35,311,000 | -32,563,000 | 84,180,000 | 156,648,000 | — | -31,978,000 |
| Dec 2022 | 0 | -25,161,000 | -26,135,000 | 45,095,000 | 87,700,000 | — | -23,122,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.96
Max Pain — expiry 2028-01-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $40.00 · spot: $69.35 · call volume: 34 · put volume: 68
Expected Move to 2028-01-21:
±$57.50
(82.91%) —
implied range
$11.85 –
$126.85
· ATM straddle on $70.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Co N.V. | $3.21B | $26.85 | — |
| IMNM | Immunome Inc. | $3.18B | $28.01 | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.11B | $24.78 | — |
| IRON | Disc Medicine, Inc. | $3.11B | $80.94 | — |
| QURE | uniQure N.V. | $3.29B | $47.46 | — |
News headlines (Yahoo Finance, 1h cache)
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
2026-08-06 12:00 · Yahoo
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
2026-07-13 20:15 · Yahoo
MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX)
2026-06-12 12:52 · Yahoo
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
2026-06-12 11:00 · Yahoo
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run
2026-05-27 19:38 · Yahoo
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-07 12:00 · Yahoo
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
2026-05-07 11:00 · Yahoo
Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhib
2026-07-07 14:31 · Yahoo
UMH Properties and 4 More Stocks See Action From Activist Investors
2026-08-14 23:05 · Yahoo
Stock Market Checklist Helps Uncover Winners In Hot Biotechs
2026-07-31 15:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.